Privia Health Group, Inc. (PRVA) Stock Price & Analysis

Privia Health Group, Inc. (PRVA) rose 2.12% to USD 25.5 as of July 25, 2026 at 02:25 UTC, according to Nexqual real-time market data.

PRVA last closed at USD 24.97; the session ranged USD 25.19–25.84 on volume of 878,089 shares. Market capitalization is $3.21B, with a 52-week range of USD 18.77–28.82 (NMS). Source: Nexqual, July 25, 2026 at 02:25 UTC.

Key Statistics (as of July 25, 2026 at 02:25 UTC)

Technical Analysis (PRVA)

Nexqual's technical model rates PRVA "BUY" based on 4 bullish and 2 bearish signals across 125 daily candles, as of July 25, 2026 at 02:25 UTC.

Analyst Ratings (PRVA)

Wall Street analysts rate PRVA "Strong Buy" based on 19 analysts, with a mean price target of USD 31.89 (range USD 24–40), per Nexqual as of July 25, 2026 at 02:25 UTC.

Earnings (PRVA)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 02:25 UTC.

Financials & Fundamentals (PRVA)

Source: Nexqual, July 25, 2026 at 02:25 UTC.

Financial Health Score (PRVA)

Nexqual rates Privia Health Group, Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 02:25 UTC.

Ownership (PRVA)

Source: Nexqual, July 25, 2026 at 02:25 UTC.

Leadership (PRVA)

Privia Health Group, Inc. is led by Parth Mehrotra (age 46), CEO & Director, per Nexqual as of July 25, 2026 at 02:25 UTC.

Major Backers & Investors (PRVA)

Notable institutional backers of Privia Health Group, Inc. include FMR, LLC, Durable Capital Partners Lp, Rubicon Founders LLC , according to Nexqual as of July 25, 2026 at 02:25 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 02:25 UTC.

From Privia Health Group, Inc.'s Latest SEC 10-K Filing (filed 2026-02-27)

Key Strengths & Strategy (as disclosed to the SEC)

• The Privia Technology Solution: Our End-to-End Technology-Enabled Platform The Privia Technology Solution streamlines the provider, patient and care team workflows focusing on each of the following aspects: (i) patient access through various avenues (patient portal, mobile app and search engine optimization), (ii) pre-visit analytics and preparation, (iii) in-person or virtual care delivery and (iv) post visit analytics, care-coordination and reporting.
• The Privia Platform is designed to succeed across demographic cohorts, acuity levels and reimbursement models, including traditional fee-for-service Medicare, the Medicare Shared Savings Program ("MSSP"), Medicare Advantage, Medicaid, commercial insurance and other existing and emerging direct contracting programs with payers and employers.
• We designed the Privia Platform to be scalable, allowing us to grow our presence in new geographic markets and guide those markets from fee-for-service ("FFS") to value-based care ("VBC"), including commercial risk, by shifting the reimbursement model and helping our Privia Providers better manage the cost of care through a focus on quality and success-based reimbursement.
• With the emergence of new technologies and market entrants, we expect to face increasing competition over time, which we believe will generally increase awareness of the need for modernized care models and other innovative solutions. 7 Table of Contents Intellectual Property We rely on a combination of trademarks, service marks, copyrights and trade secrets to protect our proprietary technology and other intellectual property.

Partnerships

• Nephron Research estimated in a December 2024 research report titled "Healthcare Services 2025 Outlook" that the "physician enablement" market in which we participate represents up to $2.4 trillion of that total healthcare spend.
• Our business model is designed to have meaningful revenue visibility, with low invested capital and attractive margin opportunity.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 02:25 UTC. This page is informational and not investment advice.